**Programme Wednesday afternoon 1st February**

14.30 – 14.40 Opening and Welcome – Nick Drager, Executive Director TBVI; [Presentation Nick Drager](http://www.tbvi.eu/wp-content/uploads/2017/02/ND_Diablerets-2017.pdf)  
**Session 1**  
TB Biomarkers: from discovery to clinical development  
Moderator: Tom Ottenhoff (Leiden University Medical Center, Netherlands); [Presentation Tom Ottenhoff](http://www.tbvi.eu/wp-content/uploads/2017/02/TO_symp-slide.pdf)

14.40 – 15.05 TB Biomarker discovery: big data & bioinformatics - Helen Fletcher (London School of Hygiene & Tropical Medicine, United Kingdom); [Presentation Helen Fletcher](http://www.tbvi.eu/wp-content/uploads/2017/02/HF_BigData_1stFeb_FletcherWebVersion.pdf)

15.05 – 15.30 TB Biomarker discovery: functional TB Biomarker assays, a progress report - Simone Joosten (Leiden University Medical Center, Netherlands) / Helen McShane (University of Oxford, United Kingdom)

15.30 – 15.55 Clinical development and validation of proteomic TB Biomarker assays - Gerhard Walzl (Stellenbosch University, South Africa);  [Presentation Gerhard Walzl](http://www.tbvi.eu/wp-content/uploads/2017/02/GW_Clin-development-and-validation-of-proteomic-biomarkers.pdf)  
15.55 – 16.25 Coffee break / snack

16.25 – 16.50 Human challenge models for Tuberculosis - Brian Robertson (Imperial College London, United Kingdom); [Presentation Brian Robertson](http://www.tbvi.eu/wp-content/uploads/2017/02/BR_Robertson-TBVI-2017.pdf)

16.50 – 17.20 Panel discussion on TB Biomarkers and human challenge models: Facilitator: Hazel Dockrell (LSHTM, United Kingdom); Stefan Kaufmann (MPIIB, Germany); Tom Scriba, (Univ. Capetown, South Africa); Brian Robertson, (Imperial, United Kingdom). Jaqui Shea, (Aeras, US)

18.30 – 19.30 Reception (Eurotel)

**Programme Thursday 2nd February 2017 (morning)**

**Session 2**  
TB vaccine R&D a strategic update - Moderator: Nick Drager (TBVI)

08.30 – 8.45 EC perspective – Hannu Laang (EC, Belgium); [Presentation Hannu Laang](http://www.tbvi.eu/wp-content/uploads/2017/02/LesDiablerets-2017-HL_01.pdf)

08.45 – 09.00 WHO perspective - Christian Lienhardt/ Martin Friede (WHO, Switzerland); [Presentation Christian Lienhardt](http://www.tbvi.eu/wp-content/uploads/2017/02/Lienhardt_TBVI_Diablerets_Feb2017b.pdf)

09.00 – 09.15 Stop TB partnership working group on vaccines - David Lewinsohn (Oregon Health & Science University, United States);  [Presentation David Lewinsohn](http://www.tbvi.eu/wp-content/uploads/2017/02/Lewinsohn-WGNV-Les-Diablerets.pdf)

**Session 3**  
Preventive and therapeutic TB vaccination to prevent AMR, treat AMR; and possibly shorten TB treatment  
Moderator: Jan Poolman (Janssen Vaccines & Prevention B.V, Netherlands)

09.15 – 09.40 Therapeutic TB vaccines: shortening TB treatment & treating DR-TB? – Mark Hatherill, (SA Tuberculosis Vaccine Initiative, South Africa); [Presentation Mark Hatherill](http://www.tbvi.eu/wp-content/uploads/2017/02/Diableret_2017_Hatherill.pdf)

09.40 – 10.05 Immunological basis for therapeutic TB vaccines: mission (im)possible? - Andrea Cooper, (University of Leicester, United Kingdom); [Presentation Andrea Cooper](http://www.tbvi.eu/wp-content/uploads/2017/02/TBVI-AMCooper-short1.pdf)

10.05 – 10.20 MDR-TB and TB vaccines – Martin Friede / Christian Lienhardt (WHO, Switzerland); [Presentation Christian Lienhardt](http://www.tbvi.eu/wp-content/uploads/2017/02/CL2_MDR_TB_TBVI_Diablerets_2017b.pdf)

10.20 – 10.45 Future drugs and treatment regimens for (DR)TB and a discussion on the role of therapeutic vaccines - Mel Spigelman (TB alliance, United States) [presentation Mel Spigelman](http://www.tbvi.eu/wp-content/uploads/2017/03/TBVI-February-2017.pptx)

10.45 – 11.15 Panel discussion: Facilitator: Jan Poolman (Janssen Vaccines & Prevention B.V.,Netherlands)  
Geneviève Inchauspé (Transgene, France); Mark Hatherill (SATVI, South Africa); Peter Andersen (SSI, Denmark); Mel Spigelman (TB alliance, United States); Sajjad Desai (Serum Institute India, India)

11.15 – 11.45 Coffee break

**Session 4**  
Updates on Vaccine Candidates & Clinical Development Strategies  
Chairs: Jacqui Shea (Aeras, United States) & Gerald Voss (TBVI, Netherlands)

11.45 – 11.55 MTBVAC - Carlos Martin (University of Zaragoza, Spain); [Presentation Carlos Martin](http://www.tbvi.eu/wp-content/uploads/2017/02/TBVI-SIMPOSIUM-MTBVAC-LesDiablerets-2-February-2017.pdf)

11.55 – 12.05 VPM1002 - Leander Grode (Vakzine Projekt Management, Germany);

12.05 – 12.15 GSK TB vaccine candidates – Olivier Van Der Meeren (GlaxoSmithKline, Belgium); [Presentation Olivier Van Der Meeren](http://www.tbvi.eu/wp-content/uploads/2017/02/TB-018-TBVI-2017-02-02-Olivier-VDM.pdf)

12.15 – 12.25 SSI vaccines - Peter Andersen (SSI, Denmark); [Presentation Peter Andersen](http://www.tbvi.eu/wp-content/uploads/2017/02/Diablerets-januar-2017-cora.pdf)

12.25 – 12.35 Virally vectored vaccines - Helen McShane (University of Oxford, United Kingdom)

12.35 – 12.45 IDRI vaccines – Tracey Day (Infectious Disease Research Institute, United States)

12.45 – 12.55 RUTI vaccine – Pere-Joan Cardona (Archivel Farma S.L. Spain); [Presentation Pere-Joan Cardona](http://www.tbvi.eu/wp-content/uploads/2017/02/PJC_RUTI-vaccine_feb17.pdf)

13.00 – 14.00 Buffet Lunch (restaurant Eurotel)